Mantovani, Alberto http://orcid.org/0000-0001-5578-236X
Allavena, Paola
Marchesi, Federica http://orcid.org/0000-0002-7212-5721
Garlanda, Cecilia http://orcid.org/0000-0002-1510-7703
Article History
Accepted: 16 June 2022
First Online: 16 August 2022
Competing interests
: A.M. has been a recipient of commercial research grants from Sigma Tau, Roche, Novartis, Compugen and Efranat, and has been a consultant/advisory board member/lecturer for Novartis, Roche, Ventana, Pierre Fabre, Verily, Abbvie, BMS, J&J, Compugen, Imcheck, Macrophage Therapeutics, AstraZeneca, Biovelocita, BG Fund, Third Rock, Verseau Therapeutics and Olatec Therapeutics. C.G. and P.A. are recipients of research grants from Imcheck and Macrophage Therapeutics. A.M. and C.G. are inventors of patents related to PTX3 and other innate immunity molecules. A.M., C.G. and P.A. receive royalties for reagents related to innate immunity.
Free to read: This content has been made available to all.